Abstract
This is the report for professionals interested to grasp big pharma' s R&D
strategy in oncology and at the same time have an extensive R&D overview of
the leukemia and lymphoma field. This extensive 500+ pages report compiles and
analyzes Deals and alliances, Drug targets, Compound types, Targeted therapy
areas, and Selection of cancer indications among the five major pharmaceutical
companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline,
Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their
respective partners they have more than 250 drugs for the treatment of cancer.
In other words, their collective R&D capacity and presence is solid enough to
set trends for the entire field of oncology drug development. Beyond trends,
all five are fiercely defining their competitive edge and advantage in
oncology and that is what this report is about. The collective force of the
above research and analysis ' decodes' these five big pharma R&D efforts into
strategy revealing and gap filing presentations. Enough to fuel and sustain
comparative benchmarking, peer group surveillance, and partnership decisions.
The report further give an in depth analysis in two important key oncology
areas; Breast- and Prostate cancer. And provide a framework but also a careful
identification and evaluation of drug candidates, technologies and competitors.
Decoding Big Pharma' s R&D Strategy in Oncology in numbers:
- Includes references to more than 250 drugs and 600 clinical/preclinical
trials
- Addresses the competitive situation on more than 80 different cancer
indications, including supportive care indications
- Special focus on Angiogenesis-, Antibody-, Apoptosis-, Protein kinase
inhibitor- and Vaccine drugs for the treatment of cancer
- The included competitive landscape between the five big pharma includes
more than 200 companies related to cancer drug development
- Last five years of deals and alliances in oncology, including almost a
hundred different key deals and alliances
- Target analysis of 119 drug targets in oncology, including molecular
function of target, target localization, type of compound for targeting,
targets affecting signaling pathways etc
- Drug compound analysis by cancer indications
Gain insight into the current challenges and commercial opportunities
associated with leukemia and Lymphoma therapy. Explore the strengths and
weaknesses associated with compounds in clinical development. Scientific
rationale for most novel therapeutics in leukemia and Lymphoma R&D, and the
results of clinical trials to date. Leukemia includes a broad variety of
histological separate disorders which make the leukemia market segmented. And
even though a high level of unmet medical need, together with its dependence
on chemotherapy, leukemia has not historically been the focus of significant
R&D investment for emerging drugs in the pharmaceutical industry. In this
report, BioSeeker does not only describe and analyze the latest years of
progress in four different market segments; CLL, CML ALL and AML, but also
provide an insight and framework to understand the complex field of leukemia
therapeutics. Provide one of the most comprehensive coverage of the R&D trends
to set the future leukemia marketplace. BioSeeker presents both an overview
and a detailed description on the progress of key drugs in Phase III and II
development, together with general descriptions on drugs and targets. We have
identified 85 drug candidates in phase II or III stage of development and more
than 50 companies are involved in the development of these drugs.
Lymphoma is a broad term encompassing a variety of cancers of the lymphatic
system. The two main groups of lymphoma in humans are Hodgkin' s disease
(characterized by the growth of Reed-Sternberg cells) and the non-Hodgkin' s
lymphoma (NHL). The lymphoma market is a complex topic and several pitfalls
await actors not well prepared. BioSeeker Group will guide thru this field and
bring structure and knowledge enables our customers to analyze opportunities.
This report will help to answer questions on the subject of additional
lymphoma treatments beyond Rituxan.
Already today it is clear that rituximab has generated substantial revenues
for the companies involved in its development. A collection of emerging facts
suggest that numerous of the new targeted therapies are agents that cannot
just be added into treatment regimens with conventional drugs. A few of them
might have isolated properties on certain biologic targets that may require to
be modulated in particular ways before or after cytotoxic chemotherapy. Among
the emerging therapeutic strategies, passive and active immunotherapies have
clearly continued to be leading strategies. Small molecule apoptotic inducers
and kinase inhibitors are as well in the forefront.
The leukemia and lymphoma scope of this report
- Thorough examination of status and impact of several novel drugs in
development
- Discussion of the challenges in current and future treatment strategies
| 
View Cart
